These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9820446)

  • 1. Assessment of the frequency and costs of posttransplantation hospitalizations in patients receiving tacrolimus versus cyclosporine.
    Neylan JF; Sullivan EM; Steinwald B; Goss TF
    Am J Kidney Dis; 1998 Nov; 32(5):770-7. PubMed ID: 9820446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes.
    Orme ME; Jurewicz WA; Kumar N; McKechnie TL
    Pharmacoeconomics; 2003; 21(17):1263-76. PubMed ID: 14986738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus versus cyclosporin in renal transplantation in Italy: cost-minimisation and cost-effectiveness analyses.
    Lazzaro C; McKechnie T; McKenna M
    J Nephrol; 2002; 15(5):580-8. PubMed ID: 12455727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cyclosporine versus tacrolimus in kidney transplants in Brazil: a cost comparison].
    Guerra Junior AA; Acúrcio Fde A; Andrade EI; Cherchiglia ML; Cesar CC; Queiroz OV; Silva GD
    Cad Saude Publica; 2010 Jan; 26(1):163-74. PubMed ID: 20209220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.
    Pirsch JD; Miller J; Deierhoi MH; Vincenti F; Filo RS
    Transplantation; 1997 Apr; 63(7):977-83. PubMed ID: 9112351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group.
    Solez K; Vincenti F; Filo RS
    Transplantation; 1998 Dec; 66(12):1736-40. PubMed ID: 9884269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of health-related quality of life in kidney transplant patients receiving tacrolimus (FK506)-based versus cyclosporine-based immunosuppression. FK506 Kidney Transplant Study Group.
    Shield CF; McGrath MM; Goss TF
    Transplantation; 1997 Dec; 64(12):1738-43. PubMed ID: 9422413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus Versus Cyclosporine as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation.
    Liu JY; You RX; Guo M; Zeng L; Zhou P; Zhu L; Xu G; Li J; Liu D
    Am J Ther; 2016; 23(3):e810-24. PubMed ID: 25299636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients.
    Hardinger KL; Bohl DL; Schnitzler MA; Lockwood M; Storch GA; Brennan DC
    Transplantation; 2005 Jul; 80(1):41-6. PubMed ID: 16003231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group.
    Mayer AD; Dmitrewski J; Squifflet JP; Besse T; Grabensee B; Klein B; Eigler FW; Heemann U; Pichlmayr R; Behrend M; Vanrenterghem Y; Donck J; van Hooff J; Christiaans M; Morales JM; Andres A; Johnson RW; Short C; Buchholz B; Rehmert N; Land W; Schleibner S; Forsythe JL; Talbot D; Pohanka E
    Transplantation; 1997 Aug; 64(3):436-43. PubMed ID: 9275110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction.
    Tsamandas AC; Pham SM; Seaberg EC; Pappo O; Kormos RL; Kawai A; Griffith BP; Zeevi A; Duquesnoy R; Fung JJ; Starzl TE; Demetris AJ
    J Heart Lung Transplant; 1997 Jul; 16(7):723-34. PubMed ID: 9257254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression.
    Miller JT; Collins CD; Stuckey LJ; Luan FL; Englesbe MJ; Magee JC; Park JM
    Pharmacotherapy; 2009 Oct; 29(10):1166-74. PubMed ID: 19792990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaco-economic study of FK 506 (Prograf) and cyclosporine A Neoral in cadaveric renal transplantation.
    Morris-Stiff G; Richards T; Singh J; Baboolal K; Balaji V; Ostrowski K; Moore R; Darby C; Lord R; Jurewicz WA
    Transplant Proc; 1998 Jun; 30(4):1285-6. PubMed ID: 9636521
    [No Abstract]   [Full Text] [Related]  

  • 15. Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen.
    Irish W; Sherrill B; Brennan DC; Lowell J; Schnitzler M
    Transplantation; 2003 Dec; 76(12):1686-90. PubMed ID: 14688516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach.
    Jürgensen JS; Arns W; Hass B
    Eur J Health Econ; 2010 Feb; 11(1):15-25. PubMed ID: 19296139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary immunosuppression with tacrolimus in kidney transplantation: three-year follow-up in a single center.
    Kim HC; Hwang EA; Han SY; Park SB; Kim HT; Cho WH
    Transplant Proc; 2004 Sep; 36(7):2082-3. PubMed ID: 15518753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of immunosuppressive regimens on the cost of liver transplantation--results from the U.S. FK506 multicenter trial.
    Lake JR; Gorman KJ; Esquivel CO; Wiesner RH; Klintmalm GB; Miller CM; Shaw BW; Gordon JA
    Transplantation; 1995 Nov; 60(10):1089-95. PubMed ID: 7482713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.
    Johnson C; Ahsan N; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; van Veldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
    Transplantation; 2000 Mar; 69(5):834-41. PubMed ID: 10755536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
    Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.